BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

@article{LingfordHughes2012BAPUG,
  title={BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP},
  author={A. R. Lingford-Hughes and Stacy Shaw Welch and Lesley Peters and D. J. Nutt},
  journal={Journal of Psychopharmacology},
  year={2012},
  volume={26},
  pages={899 - 952}
}
The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and… 

Tables from this paper

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  • T. Barnes
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2011
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness.

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder, and recommend strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.

Human pharmacology for addiction medicine: From evidence to clinical recommendations.

Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision

These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition published in 2008 and provide a clinically and scientifically relevant, evidence-based update of earlier recommendations.

Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence

Five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions.

The effects of alcohol on neurotransmitters appear to mediate the risk for alcohol use disorder : a brief update

These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition, published in 2008, and provide a clinically and scientifically relevant, evidence-based update of earlier recommendations.

Psychopharmacological treatment of young people with substance dependence: a survey of prescribing practices in England.

Questions remain about the scale of youth dependence, the use of substitute agents in maintenance treatment and the number of adolescent addiction specialists in the treatment cadre.

Canadian Guidelines on Opioid Use Disorder Among Older Adults

These guidelines provide practical and timely clinical recommendations on the prevention, assessment, and treatment of OUD in older adults within the Canadian context.

Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment

Selective serotonin reuptake inhibitors (SSRIs), especially sertraline, showed effective results in posttraumatic stress disorder and in comorbid AnxD–AUD, and buspirone, gabapentin, and pregabalin were found to be effective in comorsical AnxDs–AUD.
...

References

SHOWING 1-10 OF 642 REFERENCES

Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology

These guidelines primarily cover the pharmacological management of withdrawal, shortand longterm substitution, maintenance of abstinence and prevention of complications, where appropriate, in substance misuse, addiction and comorbidity with psychiatric disorders.

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.

  • G. Goodwin
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2009
The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder, and are presented as recommendations to aid clinical decision making for practitioners: they may also serve as a source of information for patients and carers.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  • T. Barnes
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2011
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness.

Evidence-based pharmacological treatment of substance use disorders and pathological gambling.

It is concluded that great progress has been made in the last three decades and that currently evidence-based pharmacological treatments are available for smoking cessation, alcohol and opioid dependence and pathological gambling.

Adolescent substance abuse and psychiatric comorbidities.

This activity discusses the epidemiology, assessment, and treatment of this dual diagnosis of substance abuse, substance dependence, or substance use disorder not otherwise specified in adolescents.

Treating comorbid substance use disorders in schizophrenia

While there is growing (albeit limited) evidence that integrated and well articulated interventions that encompass pharmacological and psychosocial parameters can be beneficial for people with schizophrenia and comorbid SUD, there remains a considerable gap in the literature available to inform evidence-based practice.

Treating alcohol and drug abuse : an evidence based review

The most comprehensive scientific review of its kind, it presents the findings from more than 1,600 studies on the effectiveness of different treatments, allowing them to save major resources by identifying ineffective treatments and being aware of cost-effective alternatives.

Guidelines on the management of co-occurring mental health conditions in alcohol and other drug treatment settings: how useful are they?

To examine the extent to which this resource is perceived to be relevant and useful to clinical practice, ninety-seven AOD workers from across Australia completed an online survey.

Psychosocial interventions for people with both severe mental illness and substance misuse.

There was no consistent evidence to support any one psychosocial treatment over another and more quality trials are required that adhere to proper randomization methods; use clinically valuable, reliable, and validated measurement scales; and clearly report data, including retention in treatment, relapse, and abstinence rates.

Psychoactive drug abuse in older adults.

...